DAWNZERA (AUTOINJECTOR)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DAWNZERA (AUTOINJECTOR) (DAWNZERA (AUTOINJECTOR)).
DAWNZERA (autoinjector) contains epinephrine, a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction via alpha-1 receptors, bronchodilation via beta-2 receptors, and increased heart rate and contractility via beta-1 receptors, reversing anaphylactic symptoms.
| Metabolism | Epinephrine is metabolized primarily by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) to metanephrine, normetanephrine, vanillylmandelic acid (VMA), and other metabolites. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 60-70%) with minor biliary/fecal elimination (20-30%). |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults, allowing once-daily dosing; prolonged in renal impairment. |
| Protein binding | 92-95% bound primarily to albumin. |
| Volume of Distribution | Vd is approximately 0.2-0.3 L/kg, indicating distribution mainly in extracellular fluid. |
| Bioavailability | Subcutaneous: 75-80%; intramuscular: 80-85%. |
| Onset of Action | Intramuscular injection: 30-60 minutes; subcutaneous injection: 1-2 hours. |
| Duration of Action | Duration of clinical effect is 24 hours, supporting once-daily dosing. Monitor for extended effects in renal impairment. |
60 mg subcutaneously once daily, administered at approximately the same time each day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR <30 mL/min) or end-stage renal disease, use is not recommended due to lack of data. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate to severe hepatic impairment (Child-Pugh B or C) due to lack of data. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy have not been established. |
| Geriatric use | No specific dose adjustment required; elderly patients may have increased sensitivity, but standard adult dosing is recommended. Monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DAWNZERA (AUTOINJECTOR) (DAWNZERA (AUTOINJECTOR)).
| Breastfeeding | Not recommended due to unknown excretion in human milk. M/P ratio not established. Consider risk of infant exposure given monoclonal antibody structure; likely present in milk but limited absorption from infant GI tract. |
| Teratogenic Risk | Pregnancy Category B. No evidence of fetal harm in animal studies; however, no adequate human studies. Risk cannot be excluded but is considered low. First trimester: Theoretical risk based on mechanism (CGRP antagonism); no human data. Second and third trimesters: No reported adverse fetal outcomes. |
■ FDA Black Box Warning
None.
| Serious Effects |
No absolute contraindications to epinephrine in life-threatening anaphylaxis. Relative contraindications include hypersensitivity to epinephrine or any component of the autoinjector.
| Precautions | Administration should be into the anterolateral aspect of the thigh, not into the gluteal muscle or veins. Patients with preexisting cardiovascular disease, hypertension, diabetes, hyperthyroidism, or elderly may be at increased risk of adverse effects. Use with caution in patients receiving beta-blockers or MAO inhibitors. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure and heart rate during therapy. No specific fetal monitoring required; standard prenatal care advised. |
| Fertility Effects | No known impairment of fertility in animal studies. Human data lacking; theoretical risk due to CGRP inhibition in reproductive tissues. |